Lifecore Biomedical (Lifecore Biomedical) COGS-to-Revenue : 0.67 (As of May. 2023)

View and export this data going back to 1996. Start your Free Trial

What is Lifecore Biomedical COGS-to-Revenue?

Lifecore Biomedical's Cost of Goods Sold for the three months ended in May. 2023 was $17.1 Mil. Its Revenue for the three months ended in May. 2023 was $25.5 Mil.

Lifecore Biomedical's COGS to Revenue for the three months ended in May. 2023 was 0.67.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Lifecore Biomedical's Gross Margin % for the three months ended in May. 2023 was 32.97%.

Lifecore Biomedical COGS-to-Revenue Historical Data

The historical data trend for Lifecore Biomedical's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lifecore Biomedical COGS-to-Revenue Chart

Lifecore Biomedical Annual Data

Trend

May14

May15

May16

May17

May18

May19

May20

May21

May22

May23

COGS-to-Revenue

Get a 7-Day Free Trial

0.85

0.75

0.61

0.65

0.73

Lifecore Biomedical Quarterly Data
	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23
COGS-to-Revenue	Get a 7-Day Free Trial															0.65	0.86	0.82	0.78	0.67

Lifecore Biomedical COGS-to-Revenue Calculation

Lifecore Biomedical's COGS to Revenue for the fiscal year that ended in May. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	75.284	/	103.269
	=	0.73

Lifecore Biomedical's COGS to Revenue for the quarter that ended in May. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	17.106	/	25.521
	=	0.67

Lifecore Biomedical (NAS:LFCR) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Lifecore Biomedical's Gross Margin % for the three months ended in May. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	17.106 / 25.521
	=	32.97 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Lifecore Biomedical COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Lifecore Biomedical's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Lifecore Biomedical (Lifecore Biomedical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lifecore Biomedical Inc (NAS:LFCR) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

3515 Lyman Boulevard, Chaska, MN, USA, 55318

Website

https://www.lifecore.com

Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid.

Executives

Raymond T. White	director	12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, Llc	director	12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners Holdings, Llc	director	12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, L.p. Ii	director	12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, L.p. I	director	12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners Asset Management, Llc	director	12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Christopher S Kiper	director	12121 WILSHIRE BLVD, SUITE 1240, LOS ANGELES CA 90025
Nathaniel Calloway	director	C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734
Wynnefield Partners Small Cap Value Lp I	10 percent owner	450 SEVENTH AVENUE, SUITE 509, NEW YORK NY 10123
Raymond H Diradoorian	director	C/O LANDEC CORPORATION, 2811 AIRPARK DRIVE, SANTA MARIA CA 93455
Joshua Schechter	director	C/O THE PANTRY, INC., 305 GREGSON DRIVE, CARY NC 27511
Patrick D Walsh	director	14282 FRANKLIN AVE., TUSTIN CA 92780
John D Morberg	officer: Chief Financial Officer	C/O LANDEC CORPORATION, 2811 AIRPARK DRIVE, SANTA MARIA CA 93455
Albert D. Bolles	director	CONAGRA FOODS, INC., ONE CONAGRA DRIVE, MS 1-330, OMAHA NE 68102
James G Hall	officer: Executive Vice President	3515 LYMAN BLVD., CHASKA MN 55318